Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | SHFS 0.1324 -61.39% | XXII 0.1977 -8.34% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | RBNE 0.19 -2.56% | YFOR 0.2236 -1.58% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | TQQQ 66.29 -0.20% | TSLL 9.76 -1.21% | VZ 44.66 -1.19% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | GRAB 2.79 -2.11% | AIOK 12.02 182.82% | SQQQ 39.68 0.20% | ONDS 6.2 2.99% | LABT 0.31 -36.67% | AAPL 347.725 -0.14% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | IREN 24.905 -2.37% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | NFLX 65.85 -1.79% | QID 14.55 0.14% | CLRO 3.25 69.27% | WULF 11.32 0.00%
DNGinkgo Bioworks Holdings, Inc. logo

Ginkgo Bioworks Holdings, Inc. (DNA)

New York Stock Exchange · Currency in USD
$9.99 ▲ +0.28 (+2.88%)
At close: Oct 23, 4:00 PM ET. Market closed.
$9.87 ▼ -0.12 (-1.20%)
After hours: Oct 23, 7:33 PM ET

Summary

Previous Close
$9.71
Open
$9.68
Day's Range
$9.46 – $9.99
52 Week Range
$5.37 – $18.22
Volume
1,149,795
Avg. Volume
1,789,690
Market Cap
$672.73M
Beta (5Y Monthly)
1.80
PE Ratio (TTM)
--
EPS (TTM)
-$4.68
Earnings Date
Nov 5, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$5.00

Profile: Ginkgo Bioworks Holdings, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
485
CEO
Jason Kelly
Website
ginkgo.bio

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments. The company offers cell engineering research and development solutions, as well as cell engineering tools comprising functional genomics, antibody developability, and small molecule developability, artificial intelligence models, and reconfigurable automation cart systems on its platform for use in the research, development, and commercialization of engineered organisms and derived products.

Earnings

Next report: Thu, Nov 5, 2026
EPS estimate -$0.58 · Revenue est. $21.50M
DateEst.Actual
Aug 5, 2026-$0.90-$0.75Beat
May 7, 2026-$1.21-$1.39Miss
Feb 26, 2026-$1.80-$1.42Beat
Nov 6, 2025-$1.24-$1.45Miss
Aug 7, 2025-$1.44-$1.10Beat
May 6, 2025-$1.23-$1.68Miss

Analyst view

Consensus price target
$5.00 ▼ -49.9%
Range $5.00 – $5.00
Rating: Buy
Buy 36% · Hold 27% · Sell 36%

Get free alerts on DNA and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.